Cytosorbents Corporation (CTSO) News

Cytosorbents Corporation (CTSO): $8.34

0.02 (+0.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CTSO News Items

CTSO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CTSO News Highlights

  • CTSO's 30 day story count now stands at 16.
  • Over the past 16 days, CTSO's stories per day has been in a clear downtrend, falling by about 0.79 per 2 days.
  • VIVO, SRL and BODY are the most mentioned tickers in articles about CTSO.

Latest CTSO News From Around the Web

Below are the latest news stories about Cytosorbents Corp that investors may wish to consider to help them evaluate CTSO as an investment opportunity.

Massive Growth in Disposable Hemoperfusion Market Set to Witness Huge Growth by 2027 | Biosun Pharmed, Jafron Biomedical, CytoSorbents Corporation

Hemoperfusion may be a treatment technique during which large volumes of the patients blood are passed over an adsorbent substance so as to get rid of toxic substances from the blood. Adsorption may be a process during which molecules or

OpenPR | September 15, 2021

CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery announces an upcoming live webinar to provide a global perspective on CytoSorb® blood purification therapy in COVID-19 patients on Thursday September 16, 2021, at 11 a.m. EDT / 5:00 p.m. CET. The webinar will highlight a growing body of data from seven recently published journal articles or presentations on the use of CytoSorb in more than 215 critically ill COV

Yahoo | September 14, 2021

CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces key sepsis-related events, sponsorships and studies in conjunction with World Sepsis Day today and Sepsis Awareness Month (September).

Yahoo | September 13, 2021

CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, "Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants (STAR-D)," in the United States to support FDA marketing approval. This is being performe

Yahoo | September 10, 2021

CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces a special Company webinar highlighting the topline results of CytoSorbents' U.S. CTC Multicenter Registry that demonstrate high survival using CytoSorb® in Critically Ill COVID-19 patients on ECMO, on Monday, September 13, 2021, at 5:00 p.m. EDT.

Yahoo | September 8, 2021

A Look At The Intrinsic Value Of Cytosorbents Corporation (NASDAQ:CTSO)

In this article we are going to estimate the intrinsic value of Cytosorbents Corporation ( NASDAQ:CTSO ) by estimating...

Yahoo | September 8, 2021

CytoSorbents'' Product Associated With High Survival In Critically Ill COVID-19 Patients

CytoSorbents Corporation (NASDAQ: CTSO ) has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry. The data were presented at the International Symposium on Intensive Care and Emergency Medicine. The CTC Registry included 52 consecutive critically ill COVID-19 patients Full story available on Benzinga.com

Benzinga | September 1, 2021

CytoSorbents' Product Associated With High Survival In Critically Ill COVID-19 Patients

CytoSorbents Corporation (NASDAQ: CTSO) has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry. The data were presented at the International Symposium on Intensive Care and Emergency Medicine. The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respiratory distress syndrome (ARDS) on life support with ECMO and CytoSorb. The primary outcome of 90-day ICU mortality was 27% in the CTC Registry, below the 50% in the

Yahoo | September 1, 2021

Topline Results from CytoSorbents' U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification, announced that topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry were presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) in Brussels, Belgium yesterday. The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respirat

Yahoo | September 1, 2021

Global Systemic Inflammatory Response Syndrome (SIRS) Treatment Market Analysis, Scope Significant Demand Foreseen by 2021-27 Market I Major key players-GlaxoSmithKline, AstraZeneca ,CytoSorbents Corporation, Cardinal Health, Asahi Kasei, ConvaTec, CHIESI

Systemic Inflammatory Response Syndrome (SIRS) is an overstated guard reaction of the body to a harmful stressor (contamination, injury, medical procedure, intense irritation, ischemia or reperfusion, or threat, to give some examples) to limit and afterward wipe out the endogenous

OpenPR | August 30, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7113 seconds.